Aberrant signalling by protein kinase CK2 in imatinib‐resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives

Chronic myeloid leukaemia (CML) is driven by the fusion protein Bcr‐Abl, a constitutively active tyrosine kinase playing a crucial role in initiation and maintenance of CML phenotype. Despite the great efficacy of the Bcr‐Abl‐specific inhibitor imatinib, resistance to this drug is recognized as a ma...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Oncol
Glavni autori: Borgo, Christian, Cesaro, Luca, Salizzato, Valentina, Ruzzene, Maria, Massimino, Maria Lina, Pinna, Lorenzo A., Donella-Deana, Arianna
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2013
Teme:
Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528438/
https://ncbi.nlm.nih.gov/pubmed/24012109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.08.006
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items